Novel Molecule Shows Preclinical Success in Treating Vemurafenib-Resistant Melanoma

Source: Dermatology Times, June 2022

New synthetic small molecule aims to counter drug resistance in BRAF-mutated melanomas.

A novel triphenylmethane may one day provide an option for patients with BRAF-mutated melanomas resistant to vemurafenib. Based on in vitro and in vivo results recently published in Antioxidants, said the paper’s senior author, the synthetic small molecule warrants clinical investigation.

“We invented a new compound called indolium 1. Basically, it blocks the growth of melanoma in mice through a new mechanism of action which targets the most aggressive cells in the tumor,” said Jack L. Arbiser, MD, PhD, Thomas J. Lawley Professor of Dermatology at Emory University School of Medicine in Atlanta.